Updated Safety Analysis of Encorafenib Plus Binimetinib in Patients with BRAF V600e-Mutant Metastatic NSCLC from PHAROS Study

被引：0
|
作者：
Smit, E. [1 ]
Ahn, M-J [2 ]
Dagogo-Jack, I. [3 ]
Felip, E. [4 ]
Gelsomino, F. [5 ]
Johnson, B. [6 ]
Johnson, M. [7 ]
Negrao, M. V. [8 ]
Offin, M. [9 ]
Ramalingam, S. [10 ]
Sanborn, R. [11 ]
Tsao, A. [8 ]
Wilner, K. [12 ]
Alcasid, A. [13 ]
Usari, T. [14 ]
Zhang, X. [15 ]
Riely, G. [9 ]
机构：
[1] Leiden Univ, Med Ctr, Leiden, Netherlands
[2] Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea
[3] Massachusetts Gen Hosp, Boston, MA USA
[4] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[5] IRCCS Azienda Osped Univ Bologna, Bologna, Italy
[6] Dana Farber Canc Inst, Boston, MA USA
[7] Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[9] Mem Sloan Kettering Canc Ctr, New York, NY USA
[10] Emory Univ, Winship Canc Inst, Atlanta, GA USA
[11] Providence Canc Inst, Earle A Chiles Res Inst, Providence, RI USA
[12] Pfizer, La Jolla, CA USA
[13] Pfizer, Collegeville, PA USA
[14] Pfizer, Milan, Italy
[15] Pfizer, San Francisco, CA USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期
关键词：
non-small cell lung cancer; encorafenib; binimetinib;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MA06.13
引用
收藏
页码：S77 / S78
页数：2
相关论文
共 35 条
  • [1] Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study
    Ramalingam, Suresh S.
    Carlisle, Jennifer W.
    FUTURE ONCOLOGY, 2024, 20 (33) : 2503 - 2508
  • [2] Binimetinib, encorafenib and cetuximab (BEACON Trial) combination therapy for patients with BRAF V600E-mutant metastatic colorectal cancer
    Shahjehan, F.
    Kamatham, S.
    Chandrasekharan, C.
    Kasi, P. M.
    DRUGS OF TODAY, 2019, 55 (11) : 683 - 693
  • [3] A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer
    Baik, Christina
    Cheng, Michael L.
    Dietrich, Martin
    Gray, Jhanelle E.
    Karim, Nagla A.
    ADVANCES IN THERAPY, 2024, 41 (07) : 2586 - 2605
  • [4] A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer
    Riely, Gregory J.
    Smit, Egbert F.
    Ahn, Myung-Ju
    Felip, Enriqueta
    Ramalingam, Suresh S.
    Tsao, Anne
    Johnson, Melissa
    Gelsomino, Francesco
    Esper, Raymond
    Nadal, Ernest
    Offin, Michael
    Provencio, Mariano
    Clarke, Jeffrey
    Hussein, Maen
    Otterson, Gregory A.
    Dagogo-Jack, Ibiayi
    Goldman, Jonathan W.
    Morgensztern, Daniel
    Alcasid, Ann
    Usari, Tiziana
    Wissel, Paul
    Wilner, Keith
    Pathan, Nuzhat
    Tonkovyd, Svitlana
    Johnson, Bruce E.
    FUTURE ONCOLOGY, 2024, 20 (16) : 1047 - 1055
  • [5] Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
    Planchard, David
    Besse, Benjamin
    Groen, Harry J. M.
    Hashemi, Sayed M. S.
    Mazieres, Julien
    Kim, Tae Min
    Quoix, Elisabeth
    Souquet, Pierre-Jean
    Barlesi, Fabrice
    Baik, Christina
    Villaruz, Liza C.
    Kelly, Ronan J.
    Zhang, Shirong
    Tan, Monique
    Gasal, Eduard
    Santarpia, Libero
    Johnson, Bruce E.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (01) : 103 - 115
  • [6] Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC
    Kopetz, S.
    Grothey, A.
    Van Cutsem, E.
    Yaeger, R.
    Wasan, H.
    Yoshino, T.
    Desai, J.
    Ciardiello, F.
    Loupakis, F.
    Hong, Y. S.
    Steeghs, N.
    Guren, T. K.
    Arkenau, H-T
    Garcia-Alfonso, P.
    Belani, A.
    Zhang, X.
    Tabernero, J.
    ESMO OPEN, 2022, 7 (03)
  • [7] STARBOARD: encorafenib plus binimetinib plus pembrolizumab for first-line metastatic/unresectable BRAF V600-mutant melanoma
    Schadendorf, Dirk
    Dummer, Reinhard
    Robert, Caroline
    Ribas, Antoni
    Sullivan, Ryan J.
    Panella, Timothy
    McKean, Meredith
    Santos, Edgardo S.
    Brill, Kimberli
    Polli, Anna
    di Pietro, Alessandra
    Ascierto, Paolo A.
    FUTURE ONCOLOGY, 2022, 18 (17) : 2041 - 2051
  • [8] Treatment experience with encorafenib plus binimetinib for BRAF V600-mutant metastatic melanoma: management insights for clinical practice
    Augustyn, Kourtney
    Joseph, Jocelyn
    Patel, Anisha B.
    Razmandi, Azadeh
    Ali, Amatul Noor
    Tawbi, Hussein A.
    MELANOMA RESEARCH, 2023, 33 (05) : 406 - 416
  • [9] Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
    Tabernero, J.
    Velez, L.
    Trevino, T. L.
    Grothey, A.
    Yaeger, R.
    Van Cutsem, E.
    Wasan, H.
    Desai, J.
    Ciardiello, F.
    Yoshino, T.
    Gollerkeri, A.
    Maharry, K.
    Christy-Bittel, J.
    Kopetz, S.
    ESMO OPEN, 2021, 6 (06)
  • [10] Encorafenib plus binimetinib in patients with BRAFV600-mutant non-small cell lung cancer: Phase II PHAROS study design
    Riely, Gregory J.
    Ahn, Myung-Ju
    Felip, Enriqueta
    Ramalingam, Suresh S.
    Smit, Egbert F.
    Tsao, Anne S.
    Alcasid, Ann
    Usari, Tiziana
    Wissel, Paul S.
    Wilner, Keith D.
    Johnson, Bruce E.
    FUTURE ONCOLOGY, 2022, 18 (07) : 781 - 791
1234